A A+ A++
Website  |  Global Search
Other Contacts  |  Sitemap  |  Help Desk  Help Desk
porno izle, porno, hd porno, porno, porno, porno izle, porno, sikis, izmir escort, mersin escort, rokettube, izmir escort, izmir escort
Pharma & Biotechnology
The Current Status
  • The Indian biotechnology sector is one of the fastest growing knowledge-based sectors in India and is expected to play a key role in shaping India's rapidly developing economy. Currently, India holds two per cent share of the global market. With numerous comparative advantages in terms of R&D facilities, knowledge, skills, and cost effectiveness, the biotechnology industry in India has immense potential to emerge as a global key player.

  • The Indian biotech sector's overall turnover in 2008-09 was US$ 2.51 billion, as compared to US$ 2.13 billion in 2007-08. Bio-pharma contributed US$ 1.6 billion; bio-agri nearly US$ 311.28 million, bio-industrial segment US$ 99.19 million and bio-informatics grew 15 per cent to touch US$ 45.65 million.

  • According to a report by the Confederation of Indian Industry (CII) and consultancy firm KPMG, the Indian biotechnology sector is likely to become a US$ 5 billion industry by 2010. The report stated, "India is ranked among the top 12 biotech destinations in the world and is the third biggest in Asia-Pacific in terms of the number of biotech companies."
  • India is also gaining importance as a clinical trial destination. The global clinical research outsourcing market is projected to touch US$ 23 billion by 2011, with consultancy firm KPMG estimating that India will corner 15 per cent of this in two years.
  • According to an industry survey, carried out by Association of Biotech Led Enterprises (ABLE), biotechnology industry in India has notched up a growth of 20 per cent during 2007-08 and the revenues earned were worth US$ 2.56 billion as against US$ 2.1 billion during the previous fiscal. Research services touched US$ 500 million and bio-IT (bioinformatics) was US$ 250 million.
  • Further according to the findings, going by the current trend and the new biotech policy of the central government, the sector is poised to generate US$ 13 billion-US$ 16 billion by 2015.
  • As per the survey carried out by ABLE, 56 per cent of the sector's total revenue of US$ 1.44 billion came from exports. Around 70 per cent of exports were from bio-pharma, and 26 per cent from bio-services segments.
  • India is already being globally recognised as a manufacturer of economical, high quality bulk drugs and formulations. With a huge base of talented, skilled and cost competitive manpower, and a well-developed scientific infrastructure, India has great potential to become a leading global player in biotechnology.
  • The Indian biotech market has doubled in size in the past two years, reaching a value of US$ 2.08 billion in 2006-07, compared to US$ 1.45 billion in 2005-06. The industry grew by a remarkable 31 per cent, fuelled by the rise in domestic business, exports, mergers and acquisitions and new product innovations. Over the past five years, the industry has sustained a 30 per cent growth rate.

  • The Indian market currently accounts for a little over 1.1 per cent of the global biotech market. However, its rapid growth is likely to position it as a leading player in the years to come. India already ranks third in Asia-Pacific, after Japan and Korea and among the top 12 globally.
  • The Bio-Pharma segment, continues to contribute more than two-thirds of the biotech sector revenues. It recorded sales of around US$ 1.46 billion in 2006-07 and a growth of about 27 per cent and accounts for 71 per cent of the total industry revenues.
  • The Indian biotech industry generated US$ 1.2 billion from exports alone. Almost, 58 per cent of the industry revenues in 2006-07 came from exports.
  • Bio-Pharma exports accounted for over 74 per cent of the overall export market share in 2006-07 and 61 per cent of the Bio-Pharma segment sales. Following Bio-Pharma, Bio-Services contributed about 21 per cent of the total export share.
  • The overall size of the Indian market is expected to touch US$ 5 billion by the end of this decade, and US$ 25 billion by 2015.
  • Pharma: Indian Pharmaceutical Industry has established a strong presence for itself in the global market in the last over two decades. Presently it is valued at US$ 12 billion of which the export turnover is around US$ 4.7 billion (23% increase over previous year). The industry ranks 4th in terms of volume and is 13th in terms of value. Presently Indian pharmaceutical industry is contributing around 20% in terms of value towards global generic market.
  • It is estimated that by the year 2010 this industry would have the potential to achieve a level of Rs. 100,000 Crores in formulations with bulk drug production going up from Rs. 8000 Crores to Rs. 25,000 Crores.
  • Contract Research: There are significant opportunities for India in Pharma research, process development, clinical trials and protein manufacturing. About a third of total R&D investment by the global Pharma industry, estimated at $40-50 billion, could be made in India over the next 10 years.
  • As per consultancy firm Frost & Sullivan global Pharma R&D outsourcing market is estimated as $ 25 billion by 2007. Ever increasing R&D costs are compelling Pharma companies to outsource to regions like India, China.
  • One of the advantages of outsourcing to India is the abundant data management skills available as lot of data is involved in the whole process. Another big difference is unlike generics, in case of discovery services the big Pharma desperate to reduce costs are teaming up with Indian companies. One of the India's strengths is medicinal chemistry. The cost of hiring medicinal chemist in India 1/10th of the cost in US.
  • The Indian pharmaceutical industry is driving product development and breaking new grounds in medicine research worldwide.
  • The Indian domestic pharmaceutical market was estimated to be US$ 10.76 billion in 2008 and is expected to grow at a high compound annual growth rate (CAGR) of 9.9 per cent till 2010 and thereafter at a CAGR of 9.5 per cent till 2015.
  • Currently, the Indian pharmaceutical industry is one of the world's largest and most developed, ranking 4th in volume terms and 13th in value terms. The country accounted for 8 per cent of global production and 2 per cent of world markets in pharmaceuticals in 2008.
  • The Indian pharmaceutical offshoring industry is slated to become a US$ 2.5 billion opportunity by 2012, thanks to lower R&D costs and a high-talent pool in India.
    • India exported drugs worth US$ 4.15 billion in 2007-08. Between April to December 2008, India exported pharmaceutical products worth US$ 3.77 billion.
    • A report by industry research firm, RNCOS forecasts that pharmaceutical exports will grow at a CAGR of 18.5 per cent between 2007-08 and 2011-12. This growth will be fuelled by multi-billion dollar patent expirations and growth in the global generics market.
The Market
  • Pharmaceuticals:
    • India's pharmaceuticals market is expected to grow by about 12-13 per cent in 2009, says a study by consulting firm IMS.
    • The domestic pharma retail market posted a healthy growth of 10 per cent in May over the previous month. On a moving annual total basis (April 2008 to May 2009), the organised pharma retail market grew by 10.4 per cent to US$ 7.40 billion, which was slightly higher than the previous month's value of US$ 7.32 billion, according to consulting company, ORG-IMS.
    • A recent study by Yes Bank estimates the domestic formulations market to touch US$ 21.5 billion by 2015.
    • The Indian vaccine market was worth US$ 665 million in 2007-08 and is growing at over 20 per cent. Exports contribute over US$ 360 million, while the domestic market for vaccines is US$ 300 million.
  • Rural Market
    • According to estimates rural areas account for 21 per cent of the country's pharmaceuticals market. In 2006-07, the rural Indian pharmaceuticals market was estimated at around US$ 1.4 billion, having grown at about 40 per cent in 2006-07 against 21 per cent in the previous year.
    • Elder Pharmaceuticals has earmarked US$ 8.21 million investment for a rural thrust and set up a dedicated division called 'Elvista' to spread its network to villages, towns, sub-urban/periphery markets and hinterland districts.
  • Pharmaceutical Retail
    • India has 5.5 million chemists and druggists, and the organised retail market accounts for just 2 per cent of the industry but is posting a year-on-year growth of 30-40 per cent. The country's pharmaceutical retail market is expected to cross the US$ 10 billion mark in 2010 and be worth an estimated US$ 12 billion- US$ 13 billion by 2012.

  • Generics
    • According to a report by IMS Health, the Indian generic manufacturers will grow to more than US$ 70 billion as drugs worth approximately US$ 20 billion in annual sales faced patent expiry in 2008. With nearly US$ 80 billion worth of patent-protected drugs to go off patent by 2012, Indian generic manufacturers are positioning themselves to offer generic versions of these drugs.
  • Diagnostics Outsourcing/Clinical Trials
    • The Indian diagnostics and pathology laboratory business is presently around US$ 864 million and is growing at a rate of 20 per cent annually.
    • Moreover, the US$ 200-million Indian clinical research outsourcing market will reach up to US$ 600 million by 2010, according to a joint study done by KPMG and the Confederation of Indian Industry (CII) in September 2008.
    • Government has offered tax-breaks to the pharmaceutical sector. Units are eligible for weighted tax deduction at 150 per cent for the R&D expenditure incurred.
    • Steps have been taken to streamline procedures covering development of new drug molecules, clinical research etc.
    • Government has launched two new schemes-New Millennium Indian Technology Leadership Initiative and the Drugs and Pharmaceuticals Research Programme-especially targetted at drugs and pharmaceutical research.
    • The Indian pharmaceutical industry will see tremendous growth in the coming years as consumer spending on healthcare is increasing in India. Consumer spending on healthcare is expected to increase from 7 per cent of GDP in 2007 to 13 per cent of GDP by 2015.

The Market: Bio -Pharmaceuticals
  • The Bio-pharma sector, comprising vaccines, therapeutics and diagnostics, generated revenues of around US$ 1.45 billion in 2006-07, with a growth of almost 27 per cent over the previous year.

  • India recognised as the "Vaccine Capital" of the world
    • The Indian vaccines market is experiencing strong growth The country posseces the ability to produce large volumes of traditional vaccines at low costs. Several vaccines are being procured from India in large volumes by multinational organisations such as GAVI, UNICEF, PAHO etc. According to UNICEF, India supplies more than 60 per cent of the world's requirement of basic vaccines.
    • Presently, India is one of the largest producers of traditional vaccines in the world comprising mainly of pediatric vaccines such as Anti Rabies Vaccine, Oral Polio Vaccine, Hepatitis B Vaccine and Hib. Furthermore, a UN, enabling them to supply larger vaccine quantities.
  • Diagnostics
    • The diagnostics segment at US$ 231 million, constituted 16 per cent of the Indian bio-pharma market during 2006-07. The diagnostics market showed a relatively low growth rate of about 5 per cent, mainly due to the stiff competition existing in the Indian market.
  • Major potential for plasma proteins in India
    • Hemophiliacs are the target population for players interested in plasma protein R&D. India needs about 900,000 liters of plasma proteins per year. India has been meeting this requirement so far by importing these proteins. None of the other Plasma proteins is being manufactured in India as yet.
    • The bio-services sector has growm by approximately 53 per cent in 2006-07. The sector contributed revenues of US$ 268 million to Indian biotechnology, second only to the bio-pharma sector. Bio-services is also the second fastest growing sector in Indian biotechnology after Bio-agri.
    • Bio-agri is the third largest contributor to Indian biotech industry during 2006-07 with a turnover of US$ 225 million, accounting for almost 11 per cent of the biotech pie. However, its growth rate of almost 55 per cent is the highest among all the biotech segments.
Why Tamil Nadu?
  • Tamil Nadu is rich in bio-resources. The variety of geographical terrains in the State provides tremendous biodiversity rarely seen in any other single State. The forest, agricultural and plant resource base of the State are both large and diverse and represent great market opportunity for biotechnology products. There are more than 5,000 species of flowering plants and the forest cover in the State spreads over 22,500 sq.kms. The State also has one of the largest coastlines in the country which again presents opportunities for Marine Biotechnology. The State is also fortunate to have a pool of experts in various areas of Biotechnology with experience in commercialisation of Biotech products. Tamil Nadu is thus well-placed in terms of human resources to exploit the opportunities in Biotechnology.
  • Tamil Nadu would present an attractive market for Medical Biotechnology products as it accounts for about 11% of the pharmaceutical market in the country. Apart from penicillin manufacturing and a reasonably large number of loan licence formulation units, investment in this sector within the State has been low. Hence Biotechnology presents an ideal opportunity for the State to reverse this trend.
  • The focus on Environmental Biotechnology products within the State will be in important sectors like leather and textiles.
  • There are a number of opportunities in the above segments of Biotechnology, which can be commercially exploited to create new jobs and economic wealth in the State. Many of the opportunities are based on the bio resources available within Tamil Nadu.
  • Government through TIDCO promoted TICEL BioPark in Taramani that provides common specialized infrastructure for Biotech industry. Government is now promoting the second TICEL BioPark.
Government Support
  • Anna University and many Engineering colleges offer courses in BioTechnology, Bio Informatics, etc. Abundant availability of skilled manpower is the biggest advantage the State offers.
  • Attractive Package of Incentives depending on the size of Investment and employment as per Industrial Policy 2007.
  • Infrastructure support in the form of power, water, connecting roads, drainage, etc.
  • Single window facilitation.
Tamil Nadu
Location Tamil Nadu
Location Map
Online Land Tracking Applications